We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Development of Magnetic Resonance (MR) Simulation for Treatment Planning

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00314496
Recruitment Status : Completed
First Posted : April 14, 2006
Last Update Posted : February 25, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:

Retrospectively have access to MR images of patients to develop software that:

  1. segment images
  2. convert MR values to electron density and then
  3. entered into a dose calculation system

The project involves software development of data that is already available. No intervention is made at this point.

Condition or disease

Study Design

Study Type : Observational
Actual Enrollment : 10 participants
Time Perspective: Retrospective
Official Title: Development of MR Simulation for Treatment Planning
Study Start Date : September 2005
Primary Completion Date : November 2009
Study Completion Date : November 2009
Groups and Cohorts

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patient with conform histological diagnosis of glioblastoma multiforme signed the consent forms and were willing to go for curative radiation treatment with temozolomide

Inclusion Criteria:

  • Subject 18 years of age and older
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00314496

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Principal Investigator: Gino Fallone, PhD AHS Cancer Control Alberta
More Information

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00314496     History of Changes
Other Study ID Numbers: EX-0004
First Posted: April 14, 2006    Key Record Dates
Last Update Posted: February 25, 2016
Last Verified: January 2012